Cases & Deals

Share

Wellington Partners invests in Genticel

April 2013

Client(s) Wellington Partners Advisory AG

Jones Day advised Wellington Partners Advisory AG in connection with its purchase of €4 million of Series C Preferred Stock in an €18.2 million private placement by Genticel, a developer of therapeutic vaccines against HPV infection with high-risk types. The remaining €14.2 million was provided by existing shareholders EdRIP, IDInvest, InnoBio, IRDI, and Amundi.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.